Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
Daniel A. Sweeney(University of California System), André C. Kalil(Nebraska Medical Center), Bonifride Tuyishimire(Emmes (United States)), Lori E. Dodd(National Institutes of Health), Valeria D Cantos(Emory University), Sarah L. George(Saint Louis University), John H. Beigel(National Institute of Allergy and Infectious Diseases), Hannah Jang Kim(Kaiser Permanente), Noreen A. Hynes(Johns Hopkins University), David Chien Lye(Agency for Science, Technology and Research), Neera Ahuja(Palo Alto University), Kaitlyn Cross(Emmes (United States)), Rekha R. Rapaka(University of Maryland, Baltimore), Kathleen G. Julian(Penn State Milton S. Hershey Medical Center), Tatiana Beresnev(National Institutes of Health), Nathan Erdmann(Andover Eye Associates), José G. Castro(University of Miami), David A Lindholm(Uniformed Services University of the Health Sciences), Monica Fung(University of California, San Francisco), Corri B. Levine(The University of Texas Medical Branch at Galveston), Kay M. Tomashek, Catharine I. Paules(Penn State Milton S. Hershey Medical Center), Sheetal Kandiah(Emory University), Myoung‐don Oh(Seoul National University), Willam R Short(University of Pennsylvania), Cameron R. Wolfe(Duke Medical Center), Kevin A. Grimes(Methodist Hospital), Varduhi Ghazaryan(National Institutes of Health), Stuart H. Cohen(UC Davis Comprehensive Cancer Center), Ryan C. Maves(Naval Medical Center San Diego)
Cited by 9
Related Papers
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis
|JAMA|2013|797
COVID-19 in Immunocompromised Hosts: What We Know So Far
|Clinical Infectious Diseases|2020|568